Palvella Therapeutics CSO Jeffrey S. Martini Sells $2.08M of Stock
Jeffrey S. Martini, CSO, sold 12,500 shares of Palvella Therapeutics, Inc. at $163.34 to $172.12 a share (average $166.65) in 13 transactions, worth $2.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 0 (-100.0%).
Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) filed its Q3 2026 10-Q following its 2024 merger with Legacy Palvella. The company is focused on developing its lead product candidate, QTORIN rapamycin, for rare skin diseases and reported 14,618,457 shares of common stock outstanding as of November 2, 2026.
Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.
Term
Q3 2026
“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”
Wes Kaupinen, Founder and Chief Executive Officer
“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”
Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.
Palvella Therapeutics COO Kathleen Goin Sells $537K of Stock
Kathleen Goin, COO, sold 4,313 shares of Palvella Therapeutics, Inc. at $123.62 to $126.19 a share (average $124.58) in 3 transactions, worth $537K in total on Oct 21, 2026. Shares held after the trade: 0 (-100.0%).